Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al.
In their reply, Pilot et al. report the incidence rate of second malignancies in CML patients treated with imatinib, using the epidemiological database of Novartis Pharmaceutical Corporation.
1 It includes 9518 patients treated during sponsored clinical trial and spontaneous adverse reports from 124 000 patientyears of treatment. They report that the observed incidence rate is quite similar to that expected in the general population, with 110 malignant neoplasm including 16 prostate, two urinary bladder and three kidney cancers.
Although their analysis concern a large number of patients, it remains unclear, however, how many patients were included in trials or treated outside trials and their corresponding duration of follow up. This information could be relevant, as regards to the under-reporting of adverse events for nonclinical trial patients. Moreover, their database has included patients from different institutions and nationalities (i.e. US and European). Also Pilot et al. refers to the US general epidemiological database (SEER) only (Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov)).
In our cohort, 2 the occurrence of second malignancies was observed 8-36 months from the start of imatinib (more than 20 months for four patients). Thus, with a mean time at risk of 1.16 years observed for trial patients in the Novartis database, the maturity of the Novartis study is still short to evaluate the incidence of second malignancies.
We observed three cases of prostate cancer on 189 CML patients, age being between 65 and 69 years. Considering that the incidence rate of this cancer increases substantially between 40 and 69 years, we agree that comparisons between narrowest age groups than 40-69 years would have been more accurate. However, there is currently no evidence that the US incidence rate is strictly applicable to France, one of major issue being race and ethnicity as far as prostate cancer is concerned.
In conclusion, our study concerned a small cohort of CML patients with long-term follow-up from a single institution, all previously treated with interferon. As previously discussed in our letter, our purpose was not to suggest that all imatinib treated patients would be at risk of developing second malignancies. However, there is an increasing number of patients treated with imatinib because of its remarkable efficacy and the need for a continuous administration of the drug. Thus, we will be pleased if our observation could contribute to stimulate clinicians to spontaneously report to Health Authorities long-term side effect of tyrosine kinase inhibitor. CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia Acute promyelocytic leukemia (APL) is characterized by t(15;17), and the chimeric gene PML/RARA. 1 All-trans retinoic acid (ATRA) is highly effective for newly diagnosed cases, while arsenic trioxide (As 2 O 3 ) is efficacious in relapses. The use of ATRA induction has resulted in superior disease-free survival (DFS) compared to chemotherapy.
1 The optimal combination of ATRA with chemotherapy for induction, consolidation and maintenance has rendered APL potentially curable. However, up to 20% of patients may still relapse. Prognostic factors negatively affecting DFS include high presentation leucocyte count (410 Â 10 9 /l) and low platelet count (o40 Â 10 9 /l), male gender and CD56 expression. 1 A therapeutic strategy that intensifies treatment based on risk factor stratification has been shown to improve the DFS and overall survival (OS).
2 Thus, the continued identification of prognostic factors in APL may have significant impacts on outcome.
We have shown previously that CDKN2B (alias p15) methylation was associated with an inferior DFS.
3 Recently, Teofili et al. 4 have also reported a negative prognostic impact of CDKN2B methylation. Our previous study involved patients receiving heterogeneously ATRA or chemotherapy for induction. 3 In this report, we examined the prognostic significance of CDKN2B methylation in patients uniformly treated with ATRA induction.
The diagnosis of APL was based on typical morphologic features, and confirmed by the presence of t(15;17) and/or PML/ 
